Search results
Results From The WOW.Com Content Network
Guardant Health said its blood test to detect cancer that starts in the colon or rectum got an approval from the U.S. Food and Drug Administration, with the test moving closer toward gaining ...
Shares of precision medicine company Guardant Health (NASDAQ: GH), which specializes in liquid biopsies to test for cancer, fell 10.6% through 10:05 a.m. ET Monday morning. Monday was the first ...
Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health's blood test to detect a cancer that begins in the colon or rectum. The panel voted ...
The American biotechnology company Guardant Health, which produces liquid biopsy tests to detect cancer from mutations and other modifications in blood samples, [1] was co-founded by Helmy Eltoukhy and AmirAli Talasaz during 2012–2013. [2][3] According to John Dorfman of the Pittsburgh Tribune-Review, Talasaz and Eltoukhy discovered a ...
The test is Guardant Health’s Shield blood test, and the approval is a critical step towards making it available to the general population. The approval came after a study published in the New ...
Talasaz has served on Guardant Health's board of directors since January 2013, occupying the chairman role until August 2021. [17] He also serves on the board of uLab Systems, [18] and is a founding member of the World Innovations Network. [19] In 2017, Talasaz and Eltoukhy ranked number 37 in Fortune magazine's "40 Under 40" list. [20]
Richard Burnham Lanman is an American biotechnology entrepreneur, physician scientist, and naturalist. His contributions relate to improving diagnosis and utilization of less invasive medical procedures, most recently as Global Chief Medical Officer at Guardant Health, Inc., a precision oncology company that developed a blood test replacing invasive tissue biopsies to sequence tumor DNA and ...
Updated July 29, 2024 at 9:28 AM. The Food and Drug Administration on Monday approved Guardant Health’s blood test, called Shield, to screen for colon cancer. The test isn't meant to replace ...